MAIA Biotechnology Announces Independent Director Ms. Adelina Louie Ngar Yee Made An Individual Purchase Of 19,665 Shares, And Warrants For 19,665 Shares Of Common Stock

Author: Benzinga Newsdesk | April 30, 2024 08:32am

• Original seed investor has remained top MAIA stockholder

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA's common stock as part of the Company's recent private placement of common stock and warrants to accredited investors and certain Company directors. The securities sold to the Company directors participating in the offering were issued pursuant to the Company's 2021 Equity Incentive Plan.

Vlad Vitoc, M.D., MAIA's Chairman and Chief Executive Officer, commented, "As a top investor in MAIA, we extend our deep appreciation to Adelina for both her longstanding support as director and for her participation in this offering alongside director Stan Smith and other long-term stockholders."

In previous public remarks, Ms. Louie stated her belief that MAIA is at the critical point of bringing life-changing therapies to large populations of cancer sufferers.

Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research. Most recently she was the Chief Operating Officer of Internal Audit at HSBC Group.

Posted In: MAIA